(Adnkronos) - “Il contributo di Otsuka nella cura e nella gestione delle persone affette da disturbi mentali è stato veramente decisivo e innovativo. Con l'inizio dell'attività di Otsuka nel campo della salute mentale, abbiamo avuto un farmaco completamente nuovo, l’aripiprazolo, che era somministrato prevalentemente per via orale e consentiva di gestire una serie di sintomi che con i farmaci tradizionali non era possibile affrontare, soprattutto i sintomi negativi della schizofrenia”. Lo ha detto Andrea Fiorillo, rofessore ordinario di Psichiatria e presidente eletto della Società europea di psichiatria, in occasione della conferenza stampa a Roma per celebrare il mezzo secolo di attività dell’azienda farmaceutica in Europa alla presenza di clinici, associazioni di pazienti e rappresentanti dell'Ambasciata del Giappone in Italia. Oltre ai risultati raggiunti sono stati illustrati gli obiettivi del prossimo futuro in favore di pazienti e caregiver.
Category
🗞
NewsTranscript
00:00The contribution of OTSCA to the care and management of people affected by mental illnesses has been really decisive and I would say in a single innovative word.
00:15Initially, with the start of OTSCA's activity in the field of mental health, we had a completely new drug,
00:24Brazolol, which was mainly administered orally, which allowed to manage a series of symptoms that with traditional drugs it was not possible to deal with, especially the negative symptoms of schizophrenia and the positive symptoms.
00:40With the passage of time, however, OTSCA's research has not stopped and therefore, perhaps among the first international companies, OTSCA has allowed to use this same product, this same drug, also intramuscular, injective, with a long-acting administration,
00:56therefore an administration that is carried out once a month and that actually allows patients to free themselves from the idea, from the memory of the drug, from the idea of being considered, in quotation marks, sick.
01:10Today the innovation has gone even further, OTSCA has produced the same drug that can be administered once every two months and this naturally allows to further improve the quality of life, the quality of life of patients,
01:25and also to allow a long-term approach that is more oriented to the real clinical but also social and personal needs of the person affected by schizophrenia.
01:37In recent years, it must be said that the progression of research has gone further and today, a few years ago, a drug has come out on the market, also in Italy, the Brexipiprazol,
01:48which allows today to deal with the transversal symptoms of mental illnesses and therefore effective in mood disorders such as bipolar disorder, major depression and also in schizophrenia, especially for the negative symptoms and cognitive symptoms.
02:03I must say that since we have these drugs available, the therapeutic approaches have changed a lot and also the feeling at the level of both clinicians and society in general towards the treatment of patients with mental disorders has changed a lot and I would say much more positive than in the past.